15-Lipoxygenase-1 (15-LOX-1) is transcriptionally silenced in cancer cells, and its transcription reactivation (for example, through histone deacetylase inhibitors (HDACIs)) restores apoptosis to cancer cells. However, the exact mechanism underlying 15-LOX-1 transcription reactivation in cancer cells is still undefined. Therefore, we evaluated the critical mechanisms required for 15-LOX-1 transcription reactivation in colon cancer cells. Specific HDAC1 and HDAC2 inhibition activated 15-LOX-1 transcription. 15-LOX-1 transcription was repressed through transcription repressor complex recruitment in the region of À120 to À391 of the 15-LOX-1 promoter. The nucleosome remodeling and histone deacetylase (NuRD) repression complex was recruited to this region. Depsipeptide significantly reduced the recruitment of NuRD key components (for example, metastasis-associated protein 1 (MTA1) and HDAC1) to the 15-LOX-1 promoter before 15-LOX-1 transcriptional activation. Knock down of NuRD key components (for example, MTA1 and HDAC1) by small interfering RNA (siRNA) activated 15-LOX-1 transcription, as measured by luciferase reporter assays in stably transfected SW480 cells with the 15-LOX-1 promoter construct of the À391, but not the À120 region. Relative to expression in normal tissue, MTA1 expression in colorectal cancer mucosa from colorectal cancer patients was negatively related to 15-LOX-1 expression. Thus, our results show that NuRD contributes to 15-LOX-1 transcription suppression in colon cancer cells and that HDACIs can inhibit NuRD recruitment to a promoter to activate gene transcription, as in the case of 15-LOX-1.
Introduction
The marked improvement in our understanding of the molecular mechanisms underlying tumorigenesis has led to the emergence of molecular therapeutic targeting, which holds promise for the development of more effective and better-tolerated anticancer therapies (Gibbs, 2000) . 15-Lipoxygenase-1 (15-LOX-1) is a critical enzyme for the production of various inflammation-regulatory lipid signaling mediators, including 13-S-hydroxyoctadecadienoic acid from linoleic acid (Baer et al., 1991; Brash et al., 1997) , 15-hydroxyeicosatetraenoic acid (15-HETE) and lipoxins from arachidonic acid (Takata et al., 1994; Serhan et al., 2003) , and resolvins and protectins from docosahexaenoic acid (Ariel and Serhan, 2007) . Apoptosis is restored in cancer cells, and tumor cell growth is inhibited by 13-S-HODE (Shureiqi et al., 1999; Shureiqi et al., 2000b; Wu et al., 2003) and 15-HETE (Chen et al., 2003; Hennig et al., 2007) . 15-LOX-1 is a promising molecular target because 15-LOX-1 is downregulated in various human cancers (colon (Shureiqi et al., 1999; Nixon et al., 2004; Heslin et al., 2005) , esophageal (Shureiqi et al., 2001) , breast (Jiang et al., 2006) and pancreatic (Hennig et al., 2007) cancers), and because 15-LOX-1 re-expression through pharmaceutical agents or plasmid or adenoviral vectors induces growth inhibition and re-establishes terminal differentiation and apoptosis in cancer cells (Shureiqi et al., 2000a (Shureiqi et al., , 2001 (Shureiqi et al., , 2003 Wu et al., 2003 Wu et al., , 2008 Hsi et al., 2004; Nixon et al., 2004; Deguchi et al., 2005; Heslin et al., 2005; Zuo et al., 2006) . Identifying the crucial cellular events for maintaining 15-LOX-1 transcription suppression in cancer cells will allow us to identify targets for pharmaceutical inhibition to reconstitute 15-LOX-1 expression, and thereby induce apoptosis in cancer cells.
Several mechanisms for the activation of 15-LOX-1 transcription by therapeutic agents have been proposed: global histone 4 acetylation (Kamitani et al., 2001) , (Conrad and Lu, 2000; Shankaranarayanan et al., 2001) , inhibition of GATA-6 transcription repression of the 15-LOX-1 promoter (Kamitani et al., 2000; Shureiqi et al., 2002) and 15-LOX-1 promoter DNA demethylation (Liu et al., 2004; Hsi et al., 2005) . Nonetheless, the exact mechanisms underlying the transcription reactivation of 15-LOX-1 remain unknown. For example, it is unclear whether global histone 4 acetylation activates 15-LOX-1 transcription through direct 15-LOX-1 promoter chromatin remodeling or through the expression of transcription factors that subsequently influence the 15-LOX-1 promoter. The requirement for STAT-6 to activate 15-LOX-1 transcription has been questioned on the basis of the observation that suberoylanilide hydroxamic acid (SAHA) downregulates STAT-6 (Zhang et al., 2005a) , but still activates 15-LOX-1 transcription (Hsi et al., 2004) . GATA-6 knockdown inhibits GATA-6 binding to the 15-LOX-1 promoter, but fails to activate 15-LOX-1 transcription (Shureiqi et al., 2007) . 15-LOX-1 promoter DNA demethylation is insufficient to reactivate 15-LOX-1 expression (Zuo et al., 2008) .
To identify the crucial molecular mechanisms underlying 15-LOX-1 transcription reactivation in cancer cells, we evaluated the mechanisms by which histone deacetylase inhibitors (HDACIs) activate 15-LOX-1 transcription. HDACIs, a promising class of antitumorigenic agents (Bolden et al., 2006) , are the most potent known inducers of 15-LOX-1 transcription activation (Kamitani et al., 1998 (Kamitani et al., , 2000 (Kamitani et al., , 2001 Shankaranarayanan et al., 2001; Hsi et al., 2004; Shureiqi et al., 2005 Shureiqi et al., , 2007 Zuo et al., 2008) . Both specific and nonspecific inhibitors of a large number of known HDACs have been identified (Bolden et al., 2006) . Before the current study, reports of 15-LOX-1 activation by HDACIs had been limited to nonspecific HDACIs (Kamitani et al., 1998 (Kamitani et al., , 2000 (Kamitani et al., , 2001 Shankaranarayanan et al., 2001; Hsi et al., 2004; Shureiqi et al., 2005 Shureiqi et al., , 2007 Zuo et al., 2008) . Therefore, we first determined whether depsipeptide, a selective HDAC1 and HDAC2 inhibitor (Furumai et al., 2002; Bolden et al., 2006) , activated 15-LOX-1 transcription. In a subsequent series of experiments, we identified a region in the 15-LOX-1 promoter that is targeted by the nucleosome remodeling and histone deacetylase (NuRD) complex to mediate 15-LOX-1 transcription suppression.
Results
Specific HDAC1 and HDAC2 inhibition and 15-LOX-1 transcription in colon cancer cells Treatment of Caco-2 and SW480 colon cancer cells with depsipeptide induced 15-LOX-1 mRNA expression in a concentration-and time-dependent manner starting at 0. 5 nM (higher than for control cells by 2.83-fold for Caco-2 and 14-fold for SW480 cells; Po0.0001 for all comparisons) and within 2 h in Caco-2 cells and 4 h in SW480 cells (higher than for control cells by 2.14-fold for Caco-2 and 37-fold for SW480 cells; Figure 1c) . Depsipeptide induced apoptosis in Caco-2 and SW480 colon cancer cell lines (Figure 1e and Supplementary Figure 1e ). Caffeic acid, a direct enzymatic inhibitor of 15-LOX-1 (Gleason et al., 1995) , specifically inhibits 15-LOX-1 enzymatic activity at a concentration of 2.2 mM (Shureiqi et al., 2000a) , but it had no significant effect on 15-LOX-1 transcriptional activation (Supplementary Figure  2) . Caffeic acid inhibited depsipeptide induction of apoptosis, as measured by a caspase 3 enzymatic activity assay, for all tested concentrations of depsipeptide (Figure 1e for Caco-2; Supplementary Figure 1e for SW480). Furthermore, small interfering RNA (siRNA) downregulation of 15-LOX-1 expression induced by depsipeptide or SAHA (Figures 1f and h ) significantly reduced cell growth inhibition by depsipeptide ( Figure 1g ) and SAHA (Figure 1i ) in Caco-2 cells. Similar results were observed in SW480 cells (Supplementary Figures 1f-i) .
We further tested the specificity of the effects of HDAC1 and HDAC2 on 15-LOX-1 transcription activation relative to that of other HDACs by using an siRNA approach to inhibit HDAC1-11 through siRNA transfection into Caco-2 cells. The expression of 15-LOX-1 mRNA was two or more times higher than that of nonspecific siRNA only in the case of HDAC1 and HDAC2 siRNA transfection (data not shown). HDAC1-3 siRNAs reduced targeted HDAC mRNA expression (ratio to nonspecific siRNA), but not the expression of the other HDACs (83% for HDAC1, 95% for HDAC2 and 82% for HDAC3; Figures 2a-c) . 15-LOX-1 expression levels were higher for HDAC1 and HDAC2 siRNA than they were for HDAC3 siRNA 48 h after transfection (Figure 2d ).
15-LOX-1 transcription is repressed through transcription repressor complex recruitment in the region of À120 to À391 of the 15-LOX-1 promoter We used promoter-deletion analyses to identify the region in the 15-LOX-1 promoter in which HDAC1 and HDAC2 exert their repressive effects. In transienttransfection assays of luciferase reporter constructs for the À120, À391 and À3500 to þ 18 bp regions of the 15-LOX-1 promoter, the À120 region had higher basal activity than did the À391 or À3500 regions, and depsipeptide treatment significantly increased transcription activation of the À391 and À3500 regions, but not the À120 region in SW480 and Caco-2 cell lines (Figures  3a and b ; control À120 vs À391 and À3500 regions, Po0.0013 for both Caco-2 and SW480).
Several representative clones of SW480 cells stably transfected with one of the three 15-LOX-1 promoter deletion constructs (À120, À391 or À729 to þ 18 bp sequence of the 15-LOX-1 promoter) were used for characterization. Transcription activities were 226 to 363 times higher for the À120 region of the 15-LOX-1 promoter than for the À391 and À729 regions ( Figure 3c ). Depsipeptide treatment markedly increased 15-LOX-1 promoter transcription activation for the À391 region (median of depsipeptide treated-to-control ratio, 78; range, 32-260), but only minimally for the À120 region (median of depsipeptide treated-to-control ratio, 1; range, 0.94-1.2; P ¼ 0.8; Figure 3d ). 
MTA1 and 15-LOX-1 expression in colorectal cancer
The MTA1 mRNA was higher in cancerous colorectal mucosa than in paired normal mucosa in samples from 10 of 12 tested patients ( Figure 5a ; P ¼ 0.0009). In contrast, 15-LOX-1 mRNA expression levels were higher in normal than in cancerous mucosa in samples from 11 of 12 of the same patients ( Figure 5b ; P ¼ 0.0008). MTA-1 protein expression, measured by immunohistochemistry staining, was higher in all examined cases (10/10, P ¼ 0.001; Supplementary Figure  4) . The median intensity of staining was 3 in the tumors and 0.5 in the normal tissues.
Discussion
Our findings show that NuRD recruitment to the 15-LOX-1 promoter contributes to 15-LOX-1 transcription suppression and that HDACIs can activate gene transcription through NuRD dissociation from a promoter, as in the case of 15-LOX-1 in colon cancer cells.
In our study, 15-LOX-1 transcription activation occurred through selective HDAC1 and HDAC2 inhibition. Depsipeptide, a selective HDAC1 and NuRD and 15-LOX-1 X Zuo et al HDAC2 inhibitor (Bolden et al., 2006) , activated 15-LOX-1 transcription at much lower concentrations (starting at 0.5 nM) than those required for nonspecific HDACIs (for example, 5 mM for sodium butyrate (Kamitani et al., 1998) and 1-2.5 mM for SAHA (Hsi et al., 2004) and this report)). These data suggest that 15-LOX-1 transcription suppression is more specifically related to HDAC1 and HDAC2. Early transcription activation by depsipeptide (2-4 h) suggests that depsipeptide directly modulates 15-LOX-1 transcription. Similar to nonspecific HDACIs (Hsi et al., 2004) , depsipeptide activation of 15-LOX-1 significantly contributed to its antitumorigenic effects in vitro. Depsipeptide activation of 15-LOX-1 transcription and apoptosis occurred within the same concentration range, and specific inhibition of 15-LOX-1 enzymatic activity suppressed apoptosis induction by depsipeptide. 15-LOX-1 downregulation by siRNA significantly repressed SAHA and depsipeptide ability to inhibit colon cancer cell growth. The incomplete inhibition of apoptosis is likely related to the ability of HDACIs to trigger apoptosis through mechanisms (Bolden et al., 2006) besides 15-LOX-1 transcription activation, but the current data show the significance of 15-LOX-1 as a mechanism for HDACIs' antitumorigenic effects. The delay between 15-LOX-1 mRNA (real-time PCR) and protein (western blotting) expression detection may be partly due to the higher detection sensitivity of real-time PCR than of western blotting. In addition, 15-LOX-1 is tightly regulated at the translational levels by hnRNP K and hnRNP E1 in normal cells (Ostareck et al., 1997) .
Whether an element of this translational regulation contributed to the apparent lag time between 15-LOX-1 mRNA and protein synthesis in depsipeptide-treated cancer cells cannot be determined on the basis of our current studies, which were focused on transcriptional regulation of 15-LOX-1. We further confirmed the specific role of HDAC1 and HDAC2 in 15-LOX-1 transcription suppression by siRNA knockdown experiments. We found that HDAC1 and HDAC2 downregulation activated 15-LOX-1, in contrast to other HDACs, including the other members of HDAC class I (for example, HDAC3). Thus, our data show, for the first time, the specific role of HDAC1 and HDAC2 in 15-LOX-1 transcription repression. In addition, these results suggest a mechanistic link between HDAC1 and HDAC2 upregulation (Zhu et al., 2004; Huang et al., 2005) and 15-LOX-1 downregulation (Shureiqi et al., 1999 Nixon et al., 2004; Heslin et al., 2005; Takamitsu et al., 2006) in human colonic tumorigenesis.
HDAC1 and HDAC2 act within the NuRD transcription complex to suppress 15-LOX-1 transcription. HDACs have no direct DNA-binding sites and are recruited as part of transcription repression complexes to promoters (Marks et al., 2004) . We identified the region between À120 and À391 bp of the 15-LOX-1 promoter as being the target for repression complex recruitment on the basis of our observations that basal transcription activity was profoundly suppressed for the regions upstream of À120 and that depsipeptide activated transcription for the À391, but not the À120 region.
The NuRD repression complex, which contains HDAC1 and HDAC2 as core proteins (Xue et al., 1998; Brehm et al., 1999; Zhang et al., 2005b; Manavathi and Kumar, 2007) , is a strong candidate for being the repression complex recruited to this 15-LOX-1 promoter region, according to our results. NuRD components, including the distinctive NuRD proteins MTA1 and MTA2 (Sharma et al., 2006) , were recruited to the 15-LOX-1 promoter region that we identified as the site for repressor complex recruitment. Depsipeptide induced dissociation of the NuRD components from this region before 15-LOX-1 transcription activation; however, in the control experiment, depsipeptide had no effect on HDAC3, a component of the NCoR complex. The downregulation of essential NuRD complex components, such as HDAC1, HDAC2 and MTA1, by siRNA activated transcription in the À391, but not the À120 bp region of the 15-LOX-1 promoter, whereas HDAC3 siRNA had no effect. These findings indicate that NuRD has an important and specific role in 15-LOX-1 repression. Depsipeptide effects on NuRD were not secondary to the downregulation of NuRD complex components, as the expression of essential NuRD components (for example, HDAC1 and MTA1) remained unchanged by depsipeptide treatment. Further studies are needed to determine the mechanisms by which depsipeptide causes dissociation of the NuRD complex from the promoter. Our findings also show, for the first time to our knowledge, a new mechanism for gene transcription activation by HDACIs through inhibiting NuRD recruitment to a promoter.
Metastasis-associated protein 1 overexpression in colon cancer was associated with 15-LOX-1 transcriptional suppression in human colorectal cancers. MTA1 is overexpressed in various human cancers, and MTA1 overexpression in mouse models promotes lymphoma and breast tumorigenesis (Manavathi and Kumar, 2007) . MTA1 has been reported to be overexpressed in human colon cancer at mRNA levels (Giannini and Cavallini, 2005) , but the relevance of this finding to colon cancer biology has remained undefined before this study. Our clinical findings, which also included the newly shown MTA1 upregulation at protein levels in colon cancer cells in vivo, support those of our earlier in vitro studies, and suggest that MTA1, acting as part of the NuRD complex, contributes to colonic tumorigenesis by suppressing 15-LOX-1 transcription.
In summary, our findings show that HDAC1 and HDAC2 act as part of the NuRD repression complex to suppress 15-LOX-1 transcription in cancer cells. Further studies of the mechanisms of NuRD recruitment into the 15-LOX-1 promoter will help not only to improve our understanding of the mechanism of 15-LOX-1 silencing in cancer cells but also to identify novel molecular targets for inhibiting colonic tumorigenesis. 
Materials and methods

Materials
Suberoylanilide hydroxamic acid was provided by Merck and Company Inc. (Whitehouse Station, NJ, USA) and the National Cancer Institute (Bethesda, MD, USA); depsipeptide was provided by Gloucester Pharmaceuticals Inc. (Cambridge, MA, USA) and the National Cancer Institute. Antibodies against HDAC1, HDAC2 and HDAC3 were purchased from Upstate Cell Signaling Solutions (Lake Placid, NY, USA). Anti-MTA1, anti-MTA2 and anti-Mi2 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal antiserum to recombinant human 15-LOX-1 protein was obtained as described previously (Shureiqi et al., 2003) . Caco-2 and SW480 colon cancer cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). Other reagents, molecular-grade solvents and chemicals were obtained from commercial manufacturers or as specified.
Acquisition of clinical samples
Colon biopsy specimens were obtained from colorectal cancer patients after approval by the institutional review board of each institution, as described previously (Zuo et al., 2008) . Patients' demographic and clinical characteristics were included in the analyses and are shown in Table 1 . No patients were being treated with NSAIDs at the time of the study.
Cell cultures and treatments SW480 cells were grown in RPMI 1640 medium, and Caco-2 cells were grown in Eagle's minimal essential medium (Cambrex, Walkersville, MD, USA) with L-glutamine in a humidified atmosphere containing 5% CO 2 at 37 1C. Both media contained 10% fetal bovine serum and were supplemented with 1% penicillin-streptomycin, as described previously (Shureiqi et al., 2003) . Depsipeptide and SAHA were dissolved in dimethyl sulfoxide and added to the culture media at the indicated concentrations.
Transient transfection of 15-LOX-1 deletion constructs
To identify the region of repressor recruitment in the 15-LOX-1 promoter, SW480 and Caco-2 cells were cotransfected with À120, À391, or À3500 bp to þ 18 sequence of the 15-LOX-1 promoter subcloned into the pGL4.16 (luc2CP/Hygro) vector (Promega, Madison, WI, USA), which has a luciferase reporter system (Promega), and the pSV-b-galactosidase vector (Promega) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells were treated with 5 nM depsipeptide 24 h after transfection, and luciferase activity was measured 24 h after depsipeptide treatment, as described previously (Shureiqi et al., 2003) .
Establishment of stably transfected cell lines with 15-LOX-1 promoter deletion constructs We transfected SW480 cells with 15-LOX-1 promoter deletion constructs that contained the À120, À391 or À729 to þ 18 bp sequence of the 15-LOX-1 promoter subcloned into the pGL4.16 (luc2CP/Hygro) vector (Promega). Stably transfected clones were selected using hygromycin B (Invitrogen). Representative clones for each of the three deletion constructs were used for characterization. Cells were harvested, and luciferase activity was measured using a luciferase assay kit (Promega).
siRNA transfection SW480 and Caco-2 cells were cultured to 40-50% confluence and transfected with 100 nM of a pooled mixture of four siRNA duplexes (SMARTselected or OnTarget; Dharmacon Inc., Lafayette, CO, USA) for the targeted gene (for example, MTA1 or HDACs) or with nonspecific control siRNA (Dharmacon Inc.) using Lipofectamine 2000 (Invitrogen).
RNA extraction and real-time PCR Total RNA was extracted from cells using TRI reagent (Molecular Research Center Inc., Cincinnati, OH, USA). RNA from each sample was reverse transcribed and then measured quantitatively by real-time PCR using a comparative C t method, as described previously (Shureiqi et al., 2007) .
Western blot analyses
For western blotting, protein samples were prepared, subjected to SDS-polyacrylamide gel electrophoresis under reducing conditions, and probed with rabbit polyclonal antibody to human 15-LOX-1, MTA1, or HDAC1 using methods similar to those described previously .
Chromatin immunoprecipitation (ChIP) and ChIP/real-time PCR assays Cross-linking was performed by adding formaldehyde to the cell culture medium to a final concentration of 1% and incubating the medium for 10 min at 37 1C. ChIP assays were performed using a commercial kit according to the manufacturer's protocol (Upstate Cell Signaling Solutions). Chromatin was immunoprecipitated using the indicated antibodies. The relative enrichment of transcription factors (for example, MTA1 and HDACs) was measured using ChIP/real-time PCR with the following primers and FAM dye-labeling probe: NuRD and 15-LOX-1 X Zuo et al forward, GTGTTTTCGGTCCAAATCCTTTTCT; reverse, GAGAGCAGGGAGTGGAAACC; and probe, CCTCCCG TCAAGATAGT to amplify the À283 to À215 bp region of the 15-LOX-1 promoter relative to the ATG site. Real-time PCR was performed as described previously (Zuo et al., 2008) .
Immunohistochemical evaluation of MTA1 expression
Paraffin-embedded tissue blocks were cut into 4 mm thick sections, incubated at 60 1C overnight, and deparaffinized in xylene. Sections were stained for MTA-1, as described previously (Balasenthil et al., 2006) with minor modifications that included: (a) slides were brought to a boiling temperature in 10 mM sodium citrate buffer pH 6.0 then maintained at a sub-boiling temperature for 20 min; (b) sections were incubated with 3% hydrogen peroxide and methanol for 15 min; (c) an antihuman MTA-1 primary antibody (anti-MTA1 polyclonal sc-17773, Santa Cruz Biotechnology) was used at 1:100 concentration. The specific staining of MTA1 antibody was assessed by an experienced pathologist (RB; Balasenthil et al., 2006) semiquantitatively using a 4-point scale: 0 ¼ no staining, 1 ¼ mild staining, 2 ¼ moderate staining and 3 ¼ intense staining.
Cell survival and apoptosis assays
We measured cell survival using the sulforhodamine B assay and apoptosis by measuring caspase 3 activation with a commercial kit (BD Biosciences, Clontech, Palo Alto, CA, USA), as described previously (Shureiqi et al., 2007) .
Statistical analyses
We used the t-test for two-group comparisons. For analyses involving single factors and more than two groups, we performed a one-way analysis of variance. If the overall analysis of variance test result was significant, we performed pairwise comparisons, adjusting for multiplicities using the Bonferroni correction. We analysed data involving the simultaneous consideration of two factors using two-way analysis of variance. We first tested the interaction effect, and if it was statistically significant, we performed specific comparisons to investigate which differences were driving the effect, using the Bonferroni correction to adjust for the multiple testing problem. An individual comparison was considered significant only if the P-value was less than 0.05/k, with k representing the number of comparisons performed. If the interaction effect was not significant, we tested the individual main effects. If those were significant, we determined which pairwise comparisons were significant, again adjusting for multiplicities using the Bonferroni correction. We used the sign test for nonparametric data analyses for MTA-1 protein expression (immunohistochemistry). Quantitative data log-transformation was used to account for the normal distributional assumptions underlying the methods. Data were analysed using SAS software (SAS Institute, Cary, NC, USA).
